Correction: The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine (Oncotarget (2015) 6 (4992–5004) DOI: 10.18632/oncotarget.3214)

Deok Beom Jung, Miyong Yun, Eun Ok Kim, Jaekwang Kim, Bonglee Kim, Ji Hoon Jung, Enfeng Wang, Debabrata Mukhopadhyay, Edward Hammond, Keith Dredge, Viji Shridhar, Sung Hoon Kim

Research output: Contribution to journalComment/debate

Abstract

The IHC pictures of ‘Control #1 group’ and ‘PG545 #2 group’ have been removed from Figure 6. In addition, the ‘Cyclin D1 in Control 1 group’ is mistakenly similar to the IHC picture of ‘PCNA in Gem group’ already presented in Figure 5F. The corrected Figure 6 is shown below. The authors declare that these corrections do not change the results or conclusions of this paper. (Figure presented.)

Original languageEnglish (US)
Pages (from-to)5669
Number of pages1
JournalOncotarget
Volume10
Issue number54
DOIs
StatePublished - Sep 1 2019

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Correction: The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine (Oncotarget (2015) 6 (4992–5004) DOI: 10.18632/oncotarget.3214)'. Together they form a unique fingerprint.

Cite this